Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
Zacks Investment Research on MSN16h
NTLA Genome-Editing Therapy Gets FDA's RMAT Tag for New IndicationIntellia Therapeutics NTLA announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was ...
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
Cibc World Markets Corp bought a new stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) during the fourth quarter, ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...
The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback